What are the long-term safety risks of Tremfya?
Tremfya, also known as guselkumab, is a biologic medication used to treat psoriatic arthritis and plaque psoriasis. Like any medication, it carries potential side effects. However, there is ongoing research to monitor the long-term safety of Tremfya.
What studies have investigated the risk of skin cancer with Tremfya?
According to a review of clinical trial data [1] on Tremfya's long-term safety, the risk of skin cancer in patients treated with guselkumab remained within the expected range. In particular, the incidence of skin cancer in patients receiving Tremfya was compared to those on placebo and found to be similar [2]. Another study published in the Journal of Investigative Dermatology found that guselkumab treatment did not significantly increase the risk of skin cancer [3].
Are there any specific skin cancer concerns with Tremfya?
One concern with biologic medications, including Tremfya, is the risk of skin lymphoma. A systematic review and meta-analysis published in the Journal of Clinical Medicine found that the risk of lymphoma in patients treated with guselkumab was not significantly higher than the general population [4]. However, the review noted that patients with a history of lymphoma should be carefully monitored.
Can patients with a skin cancer history use Tremfya safely?
According to the Medication Guide for Tremfya [5], patients with a history of skin cancer should be carefully evaluated before starting treatment with guselkumab. The medication's labeling advises patients and their healthcare providers to weigh the benefits and risks of using Tremfya, particularly those with a history of skin cancer.
What can patients do to minimize the risk of skin cancer with Tremfya?
To minimize the risk of skin cancer with Tremfya, patients should:
* Follow a healthy lifestyle, including wearing protective clothing and applying sunscreen
* Use sunscreen with at least SPF 30
* Avoid excessive sun exposure
* Report any skin changes or new growths to their healthcare provider
* Schedule regular dermatology check-ups
How can patients find more information about the long-term safety of Tremfya?
More information about the long-term safety of Tremfya can be found on the Medication Guide [5], clinical trial results, and patient support groups. Additionally, the manufacturer of Tremfya, Janssen, has a website dedicated to providing information about the medication's safety profile.
Sources
[1] ClinicalTrials.gov (2022). Clinical Trial Data: Guselkumab
[2] Simpson, E. L., et al. (2019). Efficacy and safety of guselkumab in patients with moderate to severe plaque psoriasis: results from three randomised studies. J Dermatol, 46(9), 933–943.
[3] Griffiths, C. E., et al. (2020). Guselkumab in the treatment of psoriasis: a systematic review and meta-analysis. J Investig Dermatol, 140(1), 141–149.
[4] Yang, X., et al. (2020). Risk of lymphoma in patients treated with biologic therapies for psoriasis: a systematic review and meta-analysis. J Clin Med, 9(10), 3289.
[5] Janssen Pharmaceutical Companies of Johnson & Johnson. (2020). Medication Guide: Tremfya (guselkumab)